Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma

A randomised, double-blind, multinational, multicentre, active-controlled, 3-way cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with moderate or severe persistent asthma

Inclusion Criteria:

• Moderate or severe asthma partly controlled with ICS or ICS/LABA
• FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value

Exclusion Criteria:

• Diagnosis of COPD
• History or current evidence of significant cardiovascular disease
• Uncontrolled concomitant disease